Skip to Content

Acacia Pharma Group PLC ACPH

Rating as of

Morningstar’s Analysis

Currency in EUR
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Acacia Pharma Group PLC is a biopharmaceutical company that focuses on developing and commercializing novel products to improve the care of patients undergoing medical treatments such as surgery, invasive procedures, or chemotherapy. Its product portfolio includes BARHEMSYS, BYFAVO, and APD403.

Royston Road, The Officers’ Mess
Cambridge, CB22 4QH, United Kingdom
T +44 1223919760
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2018
Fiscal Year End Dec 31, 2021
Stock Type
Employees 72